Nimanee Harris
Overview
Explore the profile of Nimanee Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, et al.
Br J Dermatol
. 2024 Oct;
192(2):247-260.
PMID: 39365666
Background: Pruritus, skin pain and sleep disturbance place a significant burden on individuals with moderate-to-severe atopic dermatitis (AD) and negatively affect their quality of life. Fit-for-purpose patient-reported outcome measures (PROMs)...
2.
Martin S, Shah S, Hepp Z, Harris N, Morgans A
Bladder Cancer
. 2024 Jul;
8(1):45-53.
PMID: 38994514
Background: Pain is not well described in patients with locally advanced or metastatic urothelial cancer (la/mUC). Objective: To characterize pain and assess the content validity of the Brief Pain Inventory...
3.
Martin S, Harris N, Romanus D
J Patient Rep Outcomes
. 2023 Jul;
7(1):70.
PMID: 37458805
Background: Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disease caused by deficient activity of arylsulfatase A (ASA). Treatment options for patients are limited; gene therapy based on haematopoietic stem...
4.
Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C
Contemp Clin Trials
. 2022 Jul;
120:106860.
PMID: 35901962
The Food and Drug Administration (FDA) encourages the assessment of patient-reported outcomes (PROs) in oncology clinical trials. A 2015 review showed that approximately 26% of industry-sponsored oncology trials included assessment...
5.
Romano C, Harris N, Gnanasakthy A, DAlessio D, Chandiwana D
J Patient Rep Outcomes
. 2022 Jun;
6(1):60.
PMID: 35657533
Background: Patient-reported outcome (PRO) measures are critical for assessing treatment benefit of anticancer treatments. Although PRO measures have been developed with the intention of capturing patient-centric concepts, a gap exists...
6.
Wyrwich K, Winnette R, Bender R, Gandhi K, Williams N, Harris N, et al.
Dermatol Ther (Heidelb)
. 2022 Apr;
12(5):1287.
PMID: 35399115
No abstract available.
7.
Wyrwich K, Winnette R, Bender R, Gandhi K, Williams N, Harris N, et al.
Dermatol Ther (Heidelb)
. 2021 Nov;
12(1):149-166.
PMID: 34846634
Introduction: Individuals with alopecia areata (AA) may experience significant impacts on their health-related quality of life. The novel Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire has been developed to assess...
8.
Winnette R, Martin S, Harris N, Deal L
Dermatol Ther (Heidelb)
. 2021 Mar;
11(2):599-613.
PMID: 33751494
Introduction: Although alopecia areata (AA) profoundly impacts patients' physical appearance, emotional state, and daily activities, no treatment approved for AA currently exists. Patient-reported outcome (PRO) instruments currently used to capture...
9.
Fastenau J, Rozjabek H, Qin S, McLeod L, Nelson L, Ma J, et al.
J Patient Rep Outcomes
. 2020 Nov;
4(1):99.
PMID: 33226548
Background: Physiological and behavioral factors including hunger, satiety, food intake, and cravings are health determinants contributing to obesity. Patient-reported outcome (PRO) measures focused on eating-related factors provide insight into the...
10.
Martin S, Chen K, Harris N, Vera-Llonch M, Krasner A
Adv Ther
. 2019 Jun;
36(8):1999-2009.
PMID: 31183782
Introduction: A patient-reported outcome (PRO) measure specific to chronic hypoparathyroidism is lacking to facilitate the evaluation of treatment. A PRO measure that followed the recommendations of the US Food and...